Hansa Biopharma: Convertible Note De-Risks the Case - Redeye

Redeye comments on the USD30m convertible note issued by Hansa Biopharma to Athyrium Capital Management last week. We believe it de-risks the investment case, as we estimate the company now has funding until mid- to late 2027.

Länk till analysen i sin helhet: https://www.redeye.se/research/1158063/hansa-biopharma-convertible-note-de-risks-the-case?utm_source=finwire&utm_medium=RSS